GoldenGolden
Advanced Search
Pacific Biosciences

Pacific Biosciences

A biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation

Single Molecular Real-Time (SMRT) sequencing employs a specialized flow cell with many thousands of individual picolitre wells with transparent bottoms -- zero-mode waveguides (ZMW). The polymerase is fixed to the bottom of the well and allows the DNA strand to progress through the ZMW. As a result, the system can focus on a single molecular. SMRT sequencing allows for real-time imaging of fluorescently tagged nucleotides that are synthesized along individual DNA template molecules. The sequencing reaction ends when the template and polymerase dissociate. The average read length from the PacBio instrument is approximately 2 kb, and some reads may be over 20 kb. Longer reads are especially useful for de novo assemblies of novel genomes that can span many more repeats and bases.

Highly repetitive elements found in both eukaryotic and prokaryotic genomes pose a challenge for genome assembly and make the detailed study of repetitive sequences difficult. Long-read sequencing delivers reads in excess of several or dozens of kilobases (kbs), which can span complex or repetitive regions with a single continuous read, allowing for the resolution of these large structural features. Besides considerably longer and highly accurate DNA sequences from individual unamplified molecules, it can also exhibit where methylated bases occur, thereby providing functional information about DNA methyltransferases encoded by the genome.

Pacific Biosciences provides genomic analysis systems that deliver insights for scientists who strive to resolve complex genetic challenges. PacBio sequencing offers views of genomes, transcriptomes, and epigenomes.

Timeline

April 26, 2021
Pacific Biosciences launches new HiFi Sequencing Workflow to further improve HiFi's industry leading accuracy.
February 2021
Pacific Biosciences raises a $900,000 venture round from SoftBank.
February 2013
Pacific Biosciences raises a $20,500,000 venture round from Deerfield Management.
July 14, 2010
Pacific Biosciences raises a $109,000,000 series F round from Alloy Ventures, DAG Ventures, Deerfield Management Company, Gen-Probe, Intel Capital, Kleiner Perkins Caufield & Byers, Maverick Ventures, Mohr Davidow Ventures and Sutter Hill Ventures.
July 2010
Pacific Biosciences raises a $109,000,000 series F round from Alloy Ventures, DAG Ventures, Deerfield Management Company, Gen-Probe, Intel Capital, Kleiner Perkins Caufield & Byers, Maverick Ventures, Mohr Davidow Ventures, Morgan Stanley and Sutter Hill Ventures.
October 2009
Pacific Biosciences raises a $68,000,000 series E round from Intel Capital, Kleiner Perkins Caufield & Byers, Maverick Ventures, Mohr Davidow Ventures, Monsanto, Morgan Stanley, Ontario Teachers' Pension Plan, Sutter Hill Ventures, T. Rowe Price and Wellcome Trust.
July 2008
Pacific Biosciences raises a $100,000 series E round from Alloy Ventures, DAG Ventures, Deerfield Capital Management, Intel Capital, Kleiner Perkins Caufield & Byers, Maverick Ventures, Mohr Davidow Ventures, Morgan Stanley, Redmile Group and T. Rowe Price.
January 2007
Pacific Biosciences raises a $50,000,000 series D round from Alloy Ventures, Kleiner Perkins Caufield & Byers, Maverick Ventures and Mohr Davidow Ventures.
August 2005
Pacific Biosciences raises a $7,700,000 series C round from Alloy Ventures, Kleiner Perkins Caufield & Byers and Mohr Davidow Ventures.
July 2004
Pacific Biosciences raises a $4,500,000 series B round from BR Ventures.

Funding rounds

Acquisitions

SBA Awards

Patents

Products

People

Name
Role
LinkedIn

Aaron Holiday

Investor

Aaron Talebi

Employee

Aiyesha Ma

Employee

Alex Gottschalk

Employee

Alex Hutcheson

Employee

...

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Conor Hale
June 29, 2021
FierceBiotech
Element Biosciences has more than doubled its venture capital war chest, with the goal of offering low-cost, modular hardware in a DNA sequencing market dominated by a small number of players.
BioSpace
April 26, 2021
BioSpace
HiFi Sequencing and Software v10.1 Release on the Sequel II and IIe Systems I ncreases Scalability, Improves Usability, and Unlocks Additional Sample Types to Extend the Value of HiFi Reads
Will Daniel
February 10, 2021
markets.businessinsider.com
Pacific Biosciences is set to receive a $900 million investment from SoftBank's SB NorthStar unit in the form of convertible debt.
BioSpace
June 10, 2020
BioSpace
Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that Michael Hunkapiller, Ph.D. is retiring as Chief Executive Officer and President by the end of the year. Dr. Hunkapiller plans to remain on the Board of Directors. The company als

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.